Etanercept in the treatment of vitiligo [3]

Dermatology

Volumn 215, Issue 1, 2007, Pages 84-85

  Rigopoulos, Dimitris ^a   Gregoriou, Stamatis ^a   Larios, George ^a   Moustou, Evi ^a   Belayeva Karatza, Elena ^a   Kalogeromitros, Dimitris ^b  

^a ANDREAS SYGROS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biologic agents; Etanercept; Tumor necrosis factor alpha; Vitiligo

Indexed keywords

ETANERCEPT; INTERLEUKIN 6; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; DIGITAL IMAGING; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LETTER; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; VITILIGO;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITILIGO;

EID: 34250820351     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102044     Document Type: Letter

References (11)

1. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM: Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005;210:279-285.
2. Passeron T, Ortonne JP: Physiopathology and genetics of vitiligo. J Autoimmun 2005;25(suppl):63-68.
3. Iacovelli P, Sinagra JL, Vidolin AP, Marenda S, Capitanio B, Leone G, Picardo M: Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005;210:26-30.
4. Goktay F, Mansur AT, Aydingoz IE: Colocalization of vitiligo and lichen planus on scrotal skin: a finding contrary to the actinic damage theory. Dermatology 2006;212:390-392.
5. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, Fabbri P: New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92.
6. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M: Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002;13:299-313.
7. Heenen M, Simonart T: Biological agents and psoriatic epidermis: what are we ultimately targeting? Dermatology 2006;212:321-323.
8. Van Geel N, Ongenae K, Vander Haeghen Y, Vervaet C, Naeyaert JM: Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo. Dermatology 2006;213:23-29.
9. Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-217.
10. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A: Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004;51:52-61.
11. Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE: Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 1995;139:169-182.